Missing: Hyloris Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Hyloris Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Hyloris Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Hyloris Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Hyloris Pharmaceuticals Patents
Hyloris Pharmaceuticals has filed 1 patent.
Analgesics, Hepatotoxins, Phenols, Prodrugs, Antipyretics
Analgesics, Hepatotoxins, Phenols, Prodrugs, Antipyretics
Latest Hyloris Pharmaceuticals News
Nov 22, 2022
Liège, BELGIUM Hyloris Pharmaceuticals Broadens Pipeline with a Proprietary Intranasal Product Candidate of a TRPV11 agonist (HY-083) for Idiopathic Rhinitis Hyloris targets a condition that affects up to 7% of the global adult population without any satisfactory treatment currently available The addition of this new value-added product candidate brings Hyloris toward its goal of 30 assets before 2025 Conference call Wednesday November 23rd at 4pm CET/10AM EST (details below) Regulated Information - Inside Information - Liège, Belgium – 22 November 2022 – 6PM CET – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announced the development of a new proprietary formulation – a TRPV1 agonist - administered intranasally as a spray, to treat idiopathic rhinitis. Idiopathic rhinitis is a medical disorder characterized by a collection of nasal symptoms that resemble nasal allergies and hay fever (allergic rhinitis) but are not caused by a known cause like allergens or infectious triggers. Idiopathic rhinitis features an overexpression of TRPV1 in the nasal mucosa giving rise to nasal obstruction, rhinorrhoea (colloquially: a runny nose), and/or sneezing. Hyloris’ treatment approach is to activate and depolarize TRPV1 receptors leading to restoration of a normal function of the nasal mucosa. Current treatment options for idiopathic rhinitis are not consistently successful. This leads to unnecessary and often ineffective surgery for severe cases, such as nasal septal corrections and/or inferior turbinate reductions. Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: “We are pleased to announce another value-added product candidate to add to our portfolio of programs. This proprietary intranasal product candidate with a well-known mechanism of action should solve a large unmet medical need and offer patients rapid and sustainable relief.” “Our focused strategy to acquire new value-added product candidates has brought us closer to our goal of reaching 30 assets in our portfolio before 2025. This has solidified our positioning to be a market leader in the development of value-added product candidates utilizing the expedited and cost-effective 505(b)2 regulatory strategy in the U.S. We aim to develop a low-dose application that can be administered locally via a nasal spray first in Europe before pursing global roll-out.” Peter Hellings, Full Professor at the University of Leuven, Belgium, and Chair of EUFOREA (European Forum for Research and Education in Allergy and Airways diseases), commented: ”Idiopathic rhinitis is a burdensome condition of the nasal mucosa with no satisfactory medical or surgical treatment, where attempted symptom management fails in nearly all cases. It is a chronic condition associated with interrupted sleep, irritability and poor concentration. Hence, it can be a severe detriment to quality of life and capacity to work.” “Current treatment tries to combine an antihistamine and an intranasal corticosteroid used in other rhinitis types which has yielded only poor results. For severe cases, patients often turn to surgery which is not a cure either. Our strategy is to defunctionalize the overactivated sensory nerve fibres by a targeted, local acting medicinal product and present clinical evidence of efficacy and safety.” CONFERENCE CALL Hyloris will host a conference call on Wednesday November 23rd at 4PM CET/10AM EST, in attendance of Prof. Dr. Peter Hellings. The webcast may be accessed via Microsoft Teams using the following details or by clicking here . Join on your computer or mobile app Meeting ID : 320 762 272 784 Passcode : 3VU5RS
Hyloris Pharmaceuticals Web Traffic
Hyloris Pharmaceuticals Rank
Hyloris Pharmaceuticals Frequently Asked Questions (FAQ)
When was Hyloris Pharmaceuticals founded?
Hyloris Pharmaceuticals was founded in 2013.
Where is Hyloris Pharmaceuticals's headquarters?
Hyloris Pharmaceuticals's headquarters is located at Boulevard Gustave Kleyer 17, Liege.
What is Hyloris Pharmaceuticals's latest funding round?
Hyloris Pharmaceuticals's latest funding round is IPO.
How much did Hyloris Pharmaceuticals raise?
Hyloris Pharmaceuticals raised a total of $16.43M.
Who are the investors of Hyloris Pharmaceuticals?
Investors of Hyloris Pharmaceuticals include Saffelberg Investments, Noshaq, Nomainvest and Scorpiaux.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.